Citizens upgraded Allogene Therapeutics (ALLO) to Outperform from Market Perform with a $5 price target The company provided guidance that the interim futility analysis of minimal residual disease clearance would occur in early Q2, which bolsters confidence not only in enrollment timelines, but also in ALPHA3’s probability of clinical and statistical success, the analyst tells investors in a research note. Citizens sees $1B of risk-adjusted sales for cema-cel at peak by 2033.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene outlines 2026 as program-defining year for allogeneic CAR T
- Allogene Therapeutics initiated with a Buy at UBS
- Allogene Therapeutics says favorable result for Servier in Cellectis arbitration
- Allogene Therapeutics’ ALPHA Study: A Promising Update in CAR T Cell Therapy
- Positive Outlook for Allogene Therapeutics: Buy Rating Backed by Promising Pipeline Advancements and Strong Financial Position